Windtree Therapeutics, Inc. (WINT)
OTCMKTS · Delayed Price · Currency is USD
0.0150
+0.0018 (13.64%)
At close: Mar 4, 2026
Windtree Therapeutics Employees
Windtree Therapeutics had 14 employees as of December 31, 2024. The number of employees decreased by 6 or -30.00% compared to the previous year.
Employees
14
Change
-6
Growth
-30.00%
Revenue / Employee
n/a
Profits / Employee
-$3,487,929
Market Cap
642.75K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 14 | - | - | 14 | 0 |
| Dec 31, 2022 | 20 | -13 | -39.39% | 20 | 0 |
| Dec 31, 2021 | 33 | 2 | 6.45% | 33 | 0 |
| Dec 31, 2020 | 31 | -1 | -3.13% | 31 | 0 |
| Dec 31, 2019 | 32 | -1 | -3.03% | 31 | 1 |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Scorpius Holdings | 91 |
| Hepion Pharmaceuticals | 22 |
| Altamira Therapeutics | 11 |
| Bio-Path Holdings | 10 |
| Lipella Pharmaceuticals | 7 |
| Innovation Pharmaceuticals | 4 |
| Actavia Life Sciences | 1 |
Windtree Therapeutics News
- 3 months ago - Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company - GlobeNewsWire
- 7 months ago - Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025 - GlobeNewsWire
- 7 months ago - Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption - GlobeNewsWire
- 8 months ago - Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy - GlobeNewsWire
- 8 months ago - Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions - GlobeNewsWire
- 8 months ago - Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure - GlobeNewsWire
- 8 months ago - Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel - GlobeNewsWire
- 10 months ago - Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - GlobeNewsWire